What is Cipla Ltd (CIPLA) share price return in the past 10 years?

Cipla Ltd share price has appreciated 11.6% annually (CAGR) over the past ten years.

What is the share price of Cipla Ltd (CIPLA)?

Company share prices are keep on changing according to the market conditions. The current trading price of Cipla Ltd (CIPLA) on 05-Jun-2026 16:59:59 at 16:59 is 1400.70.

What is the P/E ratio of Cipla?

The latest standalone P/E ratio of Cipla as of 05-Jun-2026 is 32.12.

What is the P/B ratio of Cipla Ltd (CIPLA)?

The latest standalone P/B ratio of Cipla Ltd (CIPLA) as of 05-Jun-2026 is 3.31.

What is the 52-week high and low of Cipla Ltd (CIPLA)?

The 52-week high of Cipla Ltd (CIPLA) is Rs. 1672.20 and the 52-week low is Rs. 1165.55.

Cipla Ltd (CIPLA) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Cipla Ltd (CIPLA)
Brand: Cipla

Key Metrics

Valuation Multiples

Market Cap

₹1,12,910 Cr.

Current Price

₹1,400.7

52-Week Low / High

₹1,166 / 1,672

TTM EPS

₹48

TTM Sales

₹28,163 Cr.

Book Value per Share

₹425.5

P/E Ratio

29.11

In line with its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

3.29

Lower than its 5-year historical median

Price to Sales (P/S)

4.01

Lower than its 5-year historical median

EV/EBITDA

16.54

Higher than its 5-year historical median

Dividend Yield

1.06%

Profitability Efficiency

Return on Equity (ROE)

11.83%

Underperforms industry median

Return on Capital Employed (ROCE)

16.00%

Underperforms industry median

Return on Assets (ROA)

9.88%

Operating Profit Margin

21%

Net Profit Margin

13.74%

Gross Profit Margin

17.2%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

2.23%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-17.41%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

-26.86%

Asset Quality

Promoter Holding

29.21%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹34,208 Cr.

Equity

₹161.6 Cr.

Face Value

₹2

All Time Low / High

₹2.22 / 1702.00

Cipla stock performance

Key Ratios

Check Before You Invest

Quality

Very Good

Check detailed performance

Valuation

Fair

Check Valuation charts

Price Trend

Strong

Check Price chart

Q.1 Is Cipla Ltd a good quality company?

Cipla Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Cipla Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Cipla Ltd vs industry peers?

Cipla Ltd revenue CAGR is 9.97%, compared to the industry median CAGR of 9.92%, indicating stable growth and maintaining its market share.

Q.1 Promoter shareholding and pledge status of Cipla Ltd?

Promoters hold 29.21% of the Cipla Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Cipla Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 10.7% based on the current price.

DeciZen - make an informed investing decision on Cipla

Consolidated basis

1. Right Stock

10 Year X-ray Pro

Long Term Prospect

2. Right Price

Price Chart

3. Right Time ⓘ

#Likely Future 5 Year CAGR.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
ROCE % ⓘ	8.3%	10.2%	11.9%	12.5%	17.9%	17.2%	18.2%	22.8%	23.6%	16%	-
Value Creation Index ⓘ	-0.3	-0.1	0.1	0.1	0.6	0.5	0.6	1.0	1.1	0.4	-
Growth Parameters ⓘ
Sales ⓘ	14,394	15,156	16,362	17,132	19,160	21,763	22,753	25,774	27,548	28,163	28,163
Sales YoY Gr.	-	5.3%	8%	4.7%	11.8%	13.6%	4.6%	13.3%	6.9%	2.2%	-
Adj EPS ⓘ	11.4	16.5	16.4	17.1	29.1	30	32.7	49.3	63.8	47	48
YoY Gr.	-	45.1%	-0.2%	3.9%	70.4%	3.2%	8.9%	50.8%	29.4%	-26.3%	-
BVPS (₹) ⓘ	155.2	175.9	185.6	194.9	226.7	257.8	289.2	329.7	384.8	425.5	425.5
Adj Net Profit ⓘ	914	1,327	1,325	1,377	2,347	2,422	2,638	3,978	5,150	3,798	3,879
Cash Flow from Ops. ⓘ	2,382	1,463	1,691	3,068	3,755	3,326	3,238	4,134	5,005	3,940	-
Debt/CF from Ops. ⓘ	1.7	2.8	2.6	0.9	0.5	0.3	0.2	0.1	0	0.1	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	7.7%	8%	7.4%	2.2%
Adj EPS ⓘ	17.1%	10.1%	12.9%	-26.3%
BVPSⓘ	11.9%	13.4%	13.7%	10.6%
Share Price	11.6%	8.2%	12.9%	-6.9%

Key Financial Parameters ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
Return on Equity % ⓘ	7.6	9.9	9.1	9	13.8	12.4	11.9	15.9	17.8	11.6	11.3
Op. Profit Mgn % ⓘ	17.6	18.7	18.9	18.7	22.2	20.7	21.9	24.4	25.9	21	21.4
Net Profit Mgn % ⓘ	6.6	8.8	8	8	12.2	11.3	11.7	15.6	18.8	13.5	13.8
Debt to Equity ⓘ	0.3	0.3	0.3	0.2	0.1	0	0	0	0	0	0
Working Cap Days ⓘ	200	210	151	140	134	135	146	145	155	159	159
Cash Conv. Cycle ⓘ	106	103	59	53	52	56	52	49	54	58	116

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Sales	14,394	15,156	16,362	17,132	19,160	21,763	22,753	25,774	27,548	28,163
Operating Expenses ⓘ +	11,919	12,329	13,265	13,951	14,911	17,251	17,763	19,483	20,425	22,280
Manufacturing Costs	1,445	1,519	1,620	1,699	1,515	1,784	1,944	2,144	2,291	2,591
Material Costs	5,317	5,438	5,784	5,991	7,352	8,496	8,252	8,820	8,929	9,549
Employee Cost	2,634	2,690	2,857	3,027	3,252	3,530	3,830	4,310	4,833	5,366
Other Costs ⓘ	2,523	2,681	3,004	3,233	2,793	3,442	3,737	4,209	4,372	4,773
Operating Profit ⓘ	2,476	2,826	3,097	3,181	4,249	4,512	4,990	6,291	7,123	5,883
Operating Profit Margin (%)	17.2%	18.6%	18.9%	18.6%	22.2%	20.7%	21.9%	24.4%	25.9%	20.9%
Other Income ⓘ +	229	358	477	369	270	322	512	747	867	882
Exceptional Items ⓘ	0	-78	0	0	0	-182	-182	-195	0	-276
Interest ⓘ	159	114	168	197	161	106	110	90	62	54
Depreciation ⓘ	1,323	1,323	1,326	1,175	1,068	1,052	1,172	1,051	1,107	1,211
Profit Before Tax ⓘ	1,222	1,669	2,079	2,178	3,290	3,493	4,038	5,702	6,821	5,224
Tax ⓘ	180	250	570	631	889	934	1,203	1,547	1,530	1,354
Profit After Tax	1,042	1,419	1,510	1,547	2,401	2,559	2,835	4,155	5,291	3,870
PAT Margin (%)	7.2%	9.4%	9.2%	9.0%	12.5%	11.8%	12.5%	16.1%	19.2%	13.7%
Adjusted EPS (₹)	12.5	17.5	19.0	19.2	29.8	31.2	34.7	51.1	65.3	48.0
Dividend Payout Ratio (%)	16%	17.10%	15.80%	20.90%	16.80%	16%	24.50%	25.50%	24.50%	27.10%

Valuation of Cipla - Consolidated

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Equity and Liabilities
Shareholders Fund +	12,482	14,163	14,955	15,710	18,284	20,798	23,346	26,620	31,079	34,369
Share Capital ⓘ	161	161	161	161	161	161	161	161	162	162
Reserves ⓘ	12,321	14,002	14,794	15,549	18,123	20,636	23,185	26,458	30,918	34,208
Debt +	4,113	4,098	4,316	2,816	1,537	810	188	247	92	258
Long Term Debt	3,645	3,662	3,830	2,369	1,203	416	0	0	12	117
Short Term Debt	467	436	486	447	335	393	188	247	80	141
Minority Interest	438	352	332	294	259	276	306	96	96	88
Trade Payables	1,571	2,119	1,948	2,282	2,067	2,508	2,535	2,474	2,837	3,230
Others Liabilities ⓘ	2,265	1,940	2,210	2,320	2,689	2,261	2,633	2,693	2,637	3,649
Total Liabilities ⓘ	20,869	22,673	23,762	23,423	24,837	26,652	29,007	32,130	36,742	41,595
Fixed Assets
Net Fixed Assets ⓘ +	9,743	9,949	9,557	9,604	9,430	9,658	9,210	9,587	9,948	12,482
Gross Block	11,353	12,960	13,790	14,914	15,647	16,968	17,205	18,161	19,656	23,825
Accumulated Depreciation	1,610	3,011	4,234	5,309	6,217	7,311	7,995	8,573	9,708	11,343
CWIP ⓘ	1,683	981	676	825	969	766	1,093	1,153	1,566	2,042
Investments ⓘ	973	1,259	2,554	1,471	2,710	2,551	3,662	5,449	7,933	8,223
Inventories	3,485	4,045	3,965	4,378	4,669	5,350	5,156	5,238	5,642	6,597
Trade Receivables	2,563	3,102	4,151	3,891	3,446	3,424	4,057	4,771	5,506	5,620
Cash Equivalents	624	966	619	1,004	1,401	1,928	1,565	875	800	1,307
Others Assets ⓘ	1,797	2,371	2,241	2,250	2,212	2,975	4,263	5,057	5,347	5,324
Total Assets ⓘ	20,869	22,673	23,762	23,423	24,837	26,652	29,007	32,130	36,742	41,595

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Cash Flow From Operating Activity ⓘ +	2,382	1,463	1,691	3,068	3,755	3,326	3,238	4,134	5,005	3,940
PBT ⓘ	1,222	1,669	2,079	2,178	3,290	3,675	4,221	5,897	6,821	5,224
Adjustment ⓘ	1,374	1,294	1,269	1,366	1,131	967	878	641	518	528
Changes in Working Capital ⓘ	235	-778	-1064	373	372	-177	-559	-806	-665	-225
Tax Paid ⓘ	-450	-722	-593	-848	-1,037	-1,140	-1,302	-1,597	-1,668	-1,586
Cash Flow From Investing Activity ⓘ +	-1,310	-854	-1,669	104	-2,387	-1,872	-2,389	-2,988	-3,691	-2,326
Capex	-1,098	-739	-504	-986	-791	-681	-1,134	-1,315	-1,504	-2,986
Net Investments	-64	-282	-1,064	1,029	-1,675	153	-913	-1,473	-2,256	54
Others ⓘ	-148	167	-101	61	80	-1,343	-341	-200	68	606
Cash Flow From Financing Activity ⓘ +	-1,326	-385	-349	-2,949	-1,240	-1,600	-958	-1,200	-1,293	-1,234
Net Proceeds from Shares ⓘ	12	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	3,420	-3	-58	-1,736	-951	-1,041	-44	0	12	93
Interest Paid ⓘ	-159	-118	-159	-164	-121	-76	-65	-65	-36	-37
Dividend Paid ⓘ	-161	-161	-242	-564	0	-403	-404	-686	-1,050	-1,292
Others ⓘ	-4,438	-104	109	-485	-168	-80	-446	-449	-219	3
Net Cash Flow ⓘ	-254	223	-326	224	129	-146	-109	-55	21	380

Financial Ratio

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Ratios
ROE (%)	8.72	10.65	10.37	10.09	14.13	13.1	12.85	16.63	18.34	11.83
ROCE (%)	8.28	10.2	11.94	12.53	17.85	17.24	18.19	22.77	23.64	16
Asset Turnover Ratio	0.7	0.7	1.03	1.15	1.17	1.15	1.11	1.16	1.08	1
PAT to CFO Conversion(x)	2.29	1.03	1.12	1.98	1.56	1.3	1.14	0.99	0.95	1.02
Working Capital Days
Receivable Days	61.40	67.90	55.40	54.10	47.40	42.20	44.10	45.50	50.60	52.10
Inventory Days	91	90.30	61.10	56.10	58.50	61.50	62	53.60	53.60	57.30
Payable Days	104.60	123.80	128.30	128.80	108	98.30	111.50	103.60	108.60	116

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Cipla Ltd FAQs

The current trading price of Cipla on 05-Jun-2026 16:59 is ₹1,400.7.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of Cipla stood at ₹1,12,910.3 Cr

The latest P/E ratio of Cipla as of 04-Jun-2026 is 32.12.

The latest P/B ratio of Cipla as of 04-Jun-2026 is 3.31.

The 52-week high of Cipla is ₹1,672.2 and the 52-week low is ₹1,165.6.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Cipla is ₹18,980 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Cipla Ltd is a good quality company.

The key valuation ratios of Cipla Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Cipla Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Cipla Ltd

Cipla Limited is a global pharmaceutical company focused on responsible and sustainable growth of complex generics and deepening portfolio in home markets of India, South Africa and North America, as well as key regulated and emerging markets. Equity Shares of the Company are listed on Bombay Stock Exchange Limited and National Stock Exchange of India Limited.

Business area of the company

The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.

Products

Generics and branded generics
Specialty
Consumer health

Awards:

2013:

Ernst & Young awarded Dr. Y K Hamied with the Lifetime Achievement Award of the year 2013
Dr. Hamied honoured with the Greatest Global Indian Living Legend Award by NDTV
Viragaonagar unit won the Excellence Award in Environment Health & Safety (EHS)
Bagged the prestigious LegalEra Award for the Best Pharmaceutical in-house Legal team.

2014

Cipla won the Global L&D Team of the Year Award
Brand, Azee bagged the Marketing Excellence Award in 2014
Won the 'Silver' award from Pharmexcil for Outstanding Performance in the export of Pharmaceuticals
Network 18 and Infosys awarded Cipla for innovation on HIV/AIDS drugs

2015:

Won the Award for Excellence in Rural Reach at India Pharma Awards
Accredited to be in Top 10 of Hot 50 Brands in Mumbai, under ‘Large Organization Category’ at the Mumbai Brand Summit
Won the Social Contributors Award at the Annual Pitch Top 50 Brands Awards organized by Dainik Bhaskar
Best Company Award to focus in Overall Nursing Home Development at the first ever CIMS Healthcare Excellence Awards
ABP News honored Dr. Y.K. Hamied with the ‘Lifetime Achievement Award’ at the Brand Excellence Awards 2015

2016:

The Indian Manufacturers’ Association (IDMA) honoured Dr. Hamied with IDMA Lifetime Achievement Award for his outstanding contribution to the Indian pharmaceutical industry.
Moroccan Society of ENT honoured Cipla Morocco team for contribution to the education of the physics.
Dr. Y.K. Hamied was honoured with the Lifetime Achievement Award at the Forbes India Leadership Awards 2016.
Won two awards for Supplier Relationship Management and People Management at the CPO Awards 2016
Received an award for Acnedep Gel packaging at the 'India Packaging Awards' 2016
Won the ABP News Healthcare Leadership Award for excellence in managing Primary Care Practitioners

2017:

Digital team bagged two of the most prestigious awards of the digital world - Digital Pioneer of the year 2017 and Best company for leveraging technology in mobile application.
ActivKids Immuno Boosters won the Emerging Nutrition Brand of the Year awarded by CIMS.
Cipla Health won a place in the Economic Times Best Asian Healthcare Brands 2017

2018:

India Packaging Awards for Excellence in Enhanced User Experience for Mesalo Foam packaging
Silver Plasticon Award 2018 for Excellence and Innovation in flexible packaging for Acnedap Plus
SCMPro Logistics and Supply Chain Awards for 'Excellence in Pharma Supply Chain Management, Procurement Transformation of the Year' and 'Best Sourcing Analytics'.
Global Logistics Excellence Award for 'Best Digital Transformation in Pharma' in the Supply Chain Practitioners category
Breathefree website bags DMA Asia Echo Award (Silver) for Best Digital Destination and Leader Certificate in Pharma & Healthcare category
India Pharma Awards for Breathefree - 'Best Patient Outreach Programme of the Year', Digital Innovation
Indian Digital Awards (IDA) for Excellence in Digital Publishing
ABP News Healthcare Leadership Award for Excellence in Improving Awareness, Detection of Health Issues and Adherence to Treatment Regimen in the Emerging Markets

2019:

Cipla receives the 18th ICSI (Institute of Company Secretaries of India) National Award for Excellence in Corporate Governance in January 2019.
Highly Commended - 'Best Working Capital Management Solution Award' at the Adam Smith Awards Asia 2019
'Innovation in Generics' Award for Sereflo at the UK Pharmacy Business Awards 2019
‘Indo-American Corporate Excellence Award' for Excellence in Manufacturing (Category II) by the Indo-American Chamber of Commerce
Most Outstanding Company in India - Healthcare category at the Asiamoney Asia’s Outstanding Companies Poll 2019

2020:

Cipla Sri Lanka is Great Place to Work Certified
Cipla is Great Place to Work Certified
‘Digital Supply Chain Enterprise Award’ at the 9th edition of the Manufacturing Supply Chain Awards 2020
Golden Peacock Award for CSR 2019 in recognition of Cipla Foundation's significant contribution towards social change
What’s Up Cipla bags the 'Best Small Idea, Big Impact Communication of the Year' at the Corp Comm & PR Excellence Awards 2020
The Institute of Chartered Accountants of India Award for Excellence in Financial Reporting 2018-19 under the category of companies publishing integrated annual report

Milestones

1935: Operations commence from a rented bungalow at 289, Bellasis Road, Bombay Central.
1939: Mahatma Gandhi visits Cipla, inspiring the Founder Dr K A Hamied to produce vital and life-saving medicines for India.
1947: Cipla celebrates India attaining Independence with a flag hoisting ceremony at Bombay Central Headquarters.
1970: Cipla becomes one of the pioneers to manufacture APIs (active pharmaceutical ingredients).
1977: Inauguration of the Cipla Research and Production Complex in Bangalore by Mrs. Luba K Hamied.
1997: Cipla Palliative Care and Training Centre is set up in Pune to provide free holistic care to terminally-ill cancer patients and their families.
2001: Cipla ushers in a new paradigm in antiretroviral therapy (ART) by offering the triple ARV FDC at USD 1-a-day, thus opening the floodgates for affordability and accessibility in HIV/AIDS treatment.
2013: Cipla acquires 100% of share capital of Cipla Medpro (South Africa).
2016: Cipla strengthens its presence in the US market with the acquisition of InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc. thus expanding its reach in the US market, with a balanced portfolio.
2017: Cipla launches Synchrobreathe, a state of-the-art innovative breath-actuated inhaler, helping millions with Obstructive Airway Diseases such as asthma.
2019: Cipla enters digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa to bring together behavioural science, real world clinical evidence and artificial intelligence to provide real time monitoring, coaching and advice to patients.
2020: Cipla leads the fight against COVID-19 through a spectrum of vital drugs that show potency against the virus. With unmatched portfolio of drugs and devices and leadership across India and key emerging markets, Cipla launches global lung leadership aspiration - Breathe. Think Cipla. In the US, the approval for generic AIbuterol MDI and successful Phase-3 completion of clinical study for generic Advair Diskus furthers this ambition.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Cipla Ltd (CIPLA)

Cipla Ltd (CIPLA)

Cipla stock performance

Check Before You Invest

Quality

Valuation

Price Trend

DeciZen - make an informed investing decision on Cipla

1. Right Stock

2. Right Price

3. Right Time ⓘ

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Cipla - Consolidated

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Cipla Ltd FAQs

What is the share price of Cipla?

What is the market cap of Cipla?

What is the P/E ratio of Cipla?

What is the P/B ratio of Cipla?

What is the 52-week high and low of Cipla?

What is the TTM revenue of Cipla?

Is Cipla Ltd a good quality company?

Is Cipla Ltd undervalued or overvalued?

Is Cipla Ltd a good buy now?

About Cipla Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.